Les Meilleurs doctors pour votre IRM d’une zone - TOP 482 des médecins

Medical Interests and Activities 

• Gastrointestinal diseases 

• Oncologic laparoscopic surgery 

• Anorectal area diseases 

• Urgent surgical cases (acute cholecystitis, divertikülit, ileus, pankreatit, appendicitis) 

• Colon and rectum cancer 

• Treatment of oncologic surgical cases with further laparoscopic and robotic surgery. • Laparoskopik hernia surgery 

• Esophagus and stomach cancer 

• Selim anorectal diseases (hemorrhoidal disease, anal fissure), perianal fistula, pilonoidal sinus (hairless- non-surgical treatment)

Education and Experience 

• İstanbul University Medical Faculty 1988 • University of Colorado Health Science Center – Intern Surgeon 

• Isparta, Dedeçam Şehit Ramazan Karaca Health Center (1995-1996) • İstanbul Surgery Hospital – American Hospital (2000-2001) 

• Chief assistant Istanbul Medical Faculty, Department of General Surgery (2001-2008) • World Congress on Peritonel Surface Malignancies (HIPEC course) Berlin, Germany (2012) 

• USC Keck School of Medicine, Los Angeles, CA, USA (2006-2007) 

• Assoc. Prof. M.D. , İstanbul Medical Faculty General Surgery (2008-2014) 

• Da Vinci Robotic Intensive Course at IRCAD, Strasbourg, France (2011) 

• Stony Brook Medicine Cadaver Training Event in Colon and Rectal Surgery, New York, USA (2016) (Instructor) 

• Fellow of the European Board of Surgery- Emergency Surgery (FEBS EmSurg) Honorary Diploma (2017) 

• Prof. M.D. , İstanbul Medical Faculty General Surgery (2014 -2017) 

• İstanbul University Medical Faculty – General Surgery Master of Science 1996 

• University of Southern California Medical Center, Department of General Surgery, Los Angeles, USA – February 2006 – February 2007

Scientific Publications • Endoscopic Laparoscopic & Minimal Invasive Surgery Journal Editorial Board / National Scientific Committee • UTACD Assist. Editor

Renseignements personnels

Nom Prénom: İbrahim COŞKUNER

Lieu de naissance - Année : 1964

Titre académique : Op. Dr.

Langue étrangère : anglais

Éducation

Faculté de médecine de l'Université de Karadeniz

Hôpital SB d'Ankara

Expérience professionnelle

Hôpital de la ville de Bursa 2020

Hôpital d'État d'Artvin 2005

Traitement de l'arthrose ; application intra-articulaire de Botox

Traitement des fractures non consolidées avec des implants composites de nouvelle génération

Utilisation d'implants composites dans la cicatrisation précoce des fractures

Remplacement articulaire dans l'arthrite de la hanche et du genou ; remplacement d'une articulation par une prothèse - implants métalliques de qualité

Applications des cellules souches dans les troubles du développement

Interventions de reconstruction pour la réparation des lésions ligamentaires du genou

Intervention chirurgicale pour le traitement de la courbure de la colonne vertébrale

Applications du système Ilizarov Traitement chirurgical des fractures ouvertes, correction des déformations

Traumatisme des structures osseuses

Chirurgie du genou

Troubles osseux structurels

Chirurgie de la main Traumatologie du sportif

Chirurgie pédiatrique

Injections intra-articulaires

Injection de PRP

Chirurgie du ligament croisé antérieur

Dr. Mert Filibeli is a specialist in Orthopedics and Traumatology. He completed his residency at the University of Health Sciences Tepecik Teaching and Research Hospital in 2017. He currently works as a surgeon at Medicalpark Hospital and İzmir University of Economics. He has also worked at Buca Seyfi Demirsoy Teaching and Research Hospital and Dr. Behçet Uz Pediatric Diseases and Surgery Teaching and Research Hospital.

Dr. Filibeli is a member of the Turkish Society of Orthopaedics and Traumatology since 2012. He has also been a member of the Turkish Orthopedics Education Council since 2017. He is fluent in English (YDS 87.5) and German (Deutsches Sprachdiplom C-2).

Dr. Burcin Kececi is a specialist in orthopedics and traumatology. He focuses on pediatric orthopedics, bone metastases, bone and soft tissue tumors, and orthopedic oncology. He performs advanced surgeries on the knee, hip, ankle, elbow, hand, and shoulder. His skills also include prosthesis replacements, limb lengthening, tendon transfers, and trauma surgery.

He received additional training in France in knee, hip, and sports injuries. He also trained in minimally invasive hip surgery. Dr. Kececi has worked at Ege University and İzmir Private Hospital. He currently practices at Medical Point İzmir Hospital. He is a member of national and international orthopedic and oncology societies, including ISOLS, SICOT, and EMSOS. He has also served on the board of TOTBİD.

Dr. Omer Burcak Binicier is a gastroenterology specialist with strong medical training. He earned his medical degree at Ege University. He completed his internal medicine and gastroenterology specialization at Dokuz Eylül University Faculty of Medicine. Dr. Binicier has over ten years of clinical experience. He has held key positions at SBÜ Tepecik Training and Research Hospital and İzmir Bayraklı City Hospital. He also gained international experience at Korea University.

Dr. Binicier diagnoses and treats a wide range of gastrointestinal diseases. His expertise includes early colon and stomach cancers, inflammatory bowel diseases, liver and pancreatic disorders, and digestive system cancers. He uses advanced endoscopic techniques such as EMR, ESD, ERCP, and endoscopic ultrasound. He is also skilled in minimally invasive obesity treatments. His clinical skills are built on years of hands-on work in top medical centers.

Faculté de médecine École de médecine Hacettepe (1994-2001)

Formation spécialisée : Hôpital de formation et de recherche d'Istanbul (2002-2008)

En 2015, il a obtenu le titre de professeur associé.

Le 1er février 2021, il a été promu au grade de professeur .

Postes professionnels :

• Médecin consultant, hôpital militaire de Balıkesir (2008-2009)

• Médecin consultant, Hôpital de formation et de recherche de Şanlıurfa (2009-2011)

• Professeur adjoint en médecine, Université Dicle, Département d'orthopédie et de traumatologie (2011-2017)

• Professeur associé MD, Université Medipol d'Istanbul, Faculté de médecine, Département d'orthopédie et de traumatologie (2017-2020)

• Professeur MD, Université Medipol d'Istanbul, Faculté de médecine, Département d'orthopédie et de traumatologie (2021 – En cours)

Le Dr Javier Albiñana Silveti est spécialiste en chirurgie orthopédique et en traumatologie pédiatrique. Il possède plus de 38 ans d'expérience dans le traitement de la dysplasie de la hanche, des tumeurs osseuses, des malformations et de la maladie de Perthes.

Expérience

2013 – présent | Traumatologie pédiatrique à l'hôpital Ruber Internacional et Quirón de Pozuelo.

2004-2013 | Chef du département d'orthopédie pédiatrique de l'hôpital La Paz de Madrid.

1994-2004 | Assistant en orthopédie pédiatrique à l'hôpital Niño Jesus de Madrid

1992-1994 | Membre associé, Département d'orthopédie pédiatrique, Université de l'Iowa (États-Unis)

1988-1989 | Chercheur en orthopédie pédiatrique, Université d'Oxford (Royaume-Uni).

Qualification

1988 | Docteur en médecine, Université autonome de Madrid.

1982 | Diplômé de la Faculté de Médecine de l'Université Autonome de Madrid.

Éducation:

2004 | Professeur associé de la Faculté de médecine de l'UAM.

Publications

2019 | L'orientation de la tête fémorale influence-t-elle le développement acétabulaire ? Une étude expérimentale de Lamb. J Pediatr Orthop. 2019 sept. ; 39(8) : 416–421.

Résultats du harnais de Pavlik dans les hanches Ortolani-positives : facteurs prédictifs d'échec et résultats arthrographiques. J Child Orthop, août 2015 ; 9(4) : 249-53.

2013 | Épiphysiodèse triradié sélective pour le traitement de la dysplasie acétabulaire expérimentale résiduelle. J Pediatr Orthop. 2013 déc. ;33(8):821-8.

Communications et présentations

2021 | Maladie de Perthes. Congrès d'orthopédie pédiatrique, SEOT, Équateur.

2019 | Dysplasie de la hanche, Hôpital pour enfants, San José, Costa Rica, avril 2019

2018 | Paralysie cérébrale, ASFAPE, Madrid.

2007 | Déchirure et dysplasie de la hanche, POSNA, San Diego.

2005 | Échec de réduction ouvert et DDH. Boston, IPOTT.

Dr. Itir Sirinoglu Temiz is a Professor of Hematology. She specializes in lymphoma, acute and chronic leukemias, multiple myeloma, thrombocytopenias, thrombosis, anemia, and bone marrow failure. She graduated with honors from Istanbul University Cerrahpaşa Faculty of Medicine. She completed her hematology training at Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital.

Dr. Sirinoglu Temiz has held key academic and administrative positions. She served as Head of Internal Medicine at IAU Faculty of Medicine. She was also Education and Administrative Manager at SBÜ Bakırköy Dr. Sadi Konuk EAH Hematology Clinic. She has broad experience in adult hematology, stem cell transplantation, and therapeutic apheresis. She currently practices at Liv Hospital.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• MR Linac
• Three Dimensional Brachytherapy
• Four Dimensional (4D) Radiotherapy
• Stereotactic RT & IMRT
• Breast Cancer, Gynecological Cancers
• Head – Neck Cancers
• Urological Tumors, Gastrointestinal Cancers
• Lung Cancer
• Central Nervous System Tumors & Metastases
• Skin Cancers
• Soft Tissue Tumors

Education:

• Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
• Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
• Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
• Liv Hospital, Radiation Oncology (2015 – Continued)
• Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
• Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
• Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
• GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
• Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
• Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
   

Experience:

• Istinye University Medical Faculty
• Liv Hospital Ulus
• Istanbul University Oncology Institution
• University of North Carolina, NC, USA
• Kocaeli University Medical Faculty
• Istanbul University, Medical Faculty

Areas of Interests

• Parkinson's disease
• Essential tremor
• Dystonia and other involuntary movements
• Balance and gait disorders
• Alzheimer's Disease and other dementias
• Spasticity
• Brain vascular diseases
• Migraine and other headaches
• Epilepsy
• Botulinum toxin application in dystonia
• Botulinum toxin application in spasticity
• Botulinum toxin application in migraine headache

Education:

• Bachelor of Medicine Ankara University 1988-1994
• Medical Specialization Neurology Ankara University Faculty of Medicine 1995-2000
• Associate Professorship Neurology Cumhuriyet University Faculty of Medicine 09/10/ 2013

Experience:

• General Practitioner Ankara Yenimahalle Health Center 1994-1995
• Research Assistant Ankara University Faculty of Medicine, Department of Neurology 1995-2000
• Specialist Dr. Sevgi Milennium Hospital 2000-2001
• Specialist Dr. Deda Brain Spinal Cord Diseases Center 2001-2002
• Specialist Dr. Pamukkale University Faculty of Medicine 2002-2003
• Specialist Dr Sivas Numune Hospital 2003-2007
• Specialist Dr. Private Sivas Anadolu Hospital 2007-2009
• Asst. Assoc. Dr. Department of Neurology, Cumhuriyet University Faculty of Medicine, Sivas 2009-2013
• Assoc Prof Dr Neurology Department AD, Cumhuriyet University Faculty of Medicine, Sivas October 2013- October 2016
• Assoc Prof Dr Medicana Sivas Hospital- March 2017-June 2020
• Assoc Prof Dr Medicana International Ankara Hospital August 2020-

Formation académique

MD, Faculté de médecine de l'Université de Chung-Ang,

Interne/Résident, Neurochirurgie, Hôpital universitaire de Chung-Ang,

Neurochirurgien certifié, hôpital universitaire de Chung-Ang,

MS en médecine, École supérieure de l'Université de Chung-Ang,

Spécialiste certifié en chirurgie mini-invasive de la colonne vertébrale (FABMISS), États-Unis,

Membre du Collège royal des médecins et chirurgiens (FRCS), Royaume-Uni

• Principales carrières

Professeur invité, Faculté de médecine de l'Université de Chung-Ang

Chef du service de neurochirurgie, Administration du personnel militaire de Daejeon / Administration du personnel militaire du nord de Gyeonggi

Chirurgie de la colonne vertébrale, directeur adjoint, département de chirurgie de la colonne vertébrale, hôpital Cheongdam Wooridul

Ancien directeur du contrôle des infections et directeur de recherche, hôpital Cheongdam Wooridul

Directeur actuel du Centre international des patients / Président du Comité de contribution sociale de l'hôpital Cheongdam Wooridul

Membre du Comité d'examen institutionnel (IRB)

Formation, Memphis Medtronic Fundamentals Course, États-Unis (2023)

Éducation, Formation sur les points de déclenchement de la douleur myofasciale (TPI) de la Société coréenne de neurochirurgie,

Ring Doctor, tournoi DoubleG FC 02

Dr. Baha Zengel is a general surgeon with expertise in breast, gallbladder, thyroid diseases, and hernia repairs. He graduated from Ege University Faculty of Medicine in 1990. In 2004, he earned a doctorate in Basic Oncology from Dokuz Eylül University. He became an Associate Professor of General Surgery in 2014 through the Inter-University Board.

Dr. Zengel is skilled in advanced surgical procedures. His experience includes skin and breast-conserving mastectomy, oncoplastic breast surgery, laparoscopic cholecystectomy, sentinel lymph node biopsy, and ROLL/SNOLL techniques. He has held important positions at Izmir Bozyaka Training and Research Hospital, including Education Officer.

He is a member of several professional associations. He serves on the Board of Directors of the Aegean Region Surgery Association and is a founding board member of the Basic Oncology Association.

Dr. Ela Simay Zengin is a neurologist. She completed her medical training at Dokuz Eylül University, Başkent University, and Acıbadem University. She has worked at Bitlis Tatvan, Sirnak, and Cizre State Hospitals.

Dr. Zengin treats Alzheimer’s disease, epilepsy, migraines, multiple sclerosis, Parkinson’s disease, and stroke. She uses advanced treatments, including apomorphine pump therapy, botulinum toxin injections, and migraine vaccines.

She is a member of the Turkish Neurology Association, American Academy of Neurology, European Academy of Neurology, and International Parkinson and Movement Disorder Society.

Dr. Ulvi Samadzade is a neurologist with training from Azerbaijan State Medical University, Gazi University, and Dokuz Eylul University Hospital. He diagnoses and treats neurological disorders such as Alzheimer’s disease, epilepsy, movement disorders, stroke, migraine, and multiple sclerosis.

Dr. Samadzade uses advanced treatments, including botulinum toxin injections, intravenous immunoglobulin (IVIG) therapy, migraine vaccines, and plasmapheresis. He practices at İzmir University of Economics Medical Point Hospital.

He is a member of several professional organizations. These include the Multiple Sclerosis Research Association, Turkish Neurological Society, European Academy of Neurology, and the International Parkinson and Movement Disorder Society (MDS).

Dr. Erkancakir is a specialist in pediatric chest diseases. He has experience with acute and chronic respiratory problems, respiratory tract infections, and bronchoscopic procedures. His areas of focus include asthma, sleep-related breathing disorders, cystic fibrosis, and tuberculosis.

He completed his medical degree at Istanbul University. He continued his specialty training at Göztepe Training and Research Hospital and Marmara University. Dr. Erkancakir has worked at leading institutions, such as Bezmialem Vakıf University and Süreyyapaşa Chest Diseases Training and Research Hospital.

He is an active member of several professional organizations, including the Turkish Thoracic Society and the European Respiratory Society. Dr. Erkancakir has received more than 20 national and international awards for his research and presentations, especially in pediatric pulmonology and cystic fibrosis.

Dr. Binnur Simsek is a gastroenterology specialist. She has experience in liver cirrhosis, portal hypertension, hepatocellular carcinoma, liver transplantation, and viral hepatitis (B, C, Delta). She also treats alcoholic and non-alcoholic fatty liver disease, peptic ulcers, gastrointestinal bleeding, and inflammatory bowel diseases such as ulcerative colitis and Crohn’s colitis.

She completed her medical and gastroenterology training at Istanbul University Faculty of Medicine. Dr. Simsek has worked at Istanbul University, Sanlıurfa Education and Research Hospital, Liv Hospital, and Istinye University. She is a member of the Turkish Association for the Study of the Liver and the Turkish Society of Gastroenterology.

Dr. Cagri Canbolat is a neurosurgeon. He specializes in neuro-oncological surgery, skull base surgery, neurovascular surgery, minimally invasive spinal surgery, oncological spinal surgery, pediatric neurosurgery, neuro-trauma, and neuro-intensive care. He completed his medical education and neurosurgery training at Cumhuriyet University Faculty of Medicine from 2005 to 2018.

Dr. Canbolat has contributed to research on the therapeutic effects of Etanercept and Ustekinumab in spinal cord injury models. He has also studied the genetics of neural tube defects. His publications include work on primary central nervous system lymphoma and surgical outcomes in elderly patients with intracranial meningioma. He has analyzed 228 cases in these studies.

He has worked at Liv Hospital Vadistanbul, Memorial Service Hospital, Acıbadem Maslak Hospital, and Vezirköprü State Hospital.

Dr Kodchanut Litleaungdej